VERU INC (VERU)

Company Profile

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. The company is headquartered in Miami, Florida and currently employs 189 full-time employees. The firm is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The firm offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Company Info

VERU INC

2916 N. Miami Avenue, Suite 1000

Miami FLORIDA 33127

P: 13125959123

CEO: Mitchell S. Steiner

Employees: 189

Website: https://verupharma.com/